17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
The US Food and Drug Administration on Friday approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients one year of age and older with late-onset Pompe disease. 7 August 2021
UK-based inhaled medicines developer Vectura, which jilted a first offer from the Carlyle Group in July in favor of a bid from tobacco company Philip Morris, today received and accepted a higher bid from the private equity firm. 6 August 2021
Data and analytics company GlobalData has weighed up the factors for consideration surrounding the prevention of thrombosis in managing COVID-19 patients. 6 August 2021
Initial results show the immune response and safety of heterogeneous regimens combining the first component of the Russian Sputnik V vaccine (Sputnik Light vaccine based on human adenovirus serotype 26) and other COVID-19 jabs. 6 August 2021
The UK Competition and Markets Authority (CMA) has provisionally found that US pharma giant Pfizer and its UK distributor Flynn Pharma, abused their dominant positions to overcharge the NHS for vital anti-epilepsy drugs, after reassessing the case. 6 August 2021
German life sciences company Merck KGaA was trading 6% higher in the stock market on Thursday afternoon after presenting a strong set of financial results for the second quarter of 2021. 5 August 2021
Danish diabetes care giant Novo Nordisk’s shares closed up nearly 5% at 611 Danish kroner yesterday, as it reported financials for the first half of 2021, showing that sales increased by 5% in kroner and by 12% at constant exchange ratels (CER) to 66.8 billion kroner $10.65 billion). 5 August 2021
The US Food and Drug Administration’s recent approval of Aduhelm (aducanumab) to treat patients with Alzheimer's disease using the accelerated approval pathway has been questioned and now this is to be investigated by the Office of the Inspector General at the Department of Health and Human Services. 5 August 2021
The US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, in March to select the influenza viruses for the composition of the influenza vaccine for the 2021-2022 US influenza season. 5 August 2021
Patients in the USA with peripheral T-cell lymphoma (PTCL) who have received at least one prior therapy will no longer be given Istodax (romidepsin). 4 August 2021
A major UK trial of cannabis-based drug Sativex in treating the most aggressive form of brain tumor is to launch at 15 National Health Service (NHS) hospitals, following promising results from a Phase I study in 27 patients. 4 August 2021
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Argentina’s Laboratorios Richmond SACIF pharmaceutical company announced the Sputnik V vaccine produced at company’s facilities will become available for vaccination in Argentina starting from this week following successful quality control of test samples at the Gamaleya Center on August 3. 4 August 2021
US drugmaker Eli Lilly saw its revenue rise by 23% in the second quarter of 2021, which amounts to a 12% jump when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. 3 August 2021
ParaPRO, a specialty pharma company focused on innovative anti-parasitic treatments, has announced the availability of Natroba (spinosad) Topical Suspension, 0.9%, the first product for scabies to be approved by the US Food and Drug Administration (FDA) in more than 30 years. 3 August 2021
Following a successful financial year 2020, German family-owned pharma major Boehringer Ingelheim says it has continued its positive trend in the first half of 2021. 3 August 2021
Finnish drugmaker Orion Corp has entered into an agreement to distribute US biopharma firm Marinus Pharmaceuticals’ CNS-selective GABAA modulator, ganaxolone, as a treatment for orphan, genetic disorders ganaxolone, across Europe. 3 August 2021
Ukraine may become one of the European centers for clinical trials and studies of original Western drugs in years to come, according to recent statements by some leading local state officials and the Ukraine media reports. 3 August 2021
Privately-held FluGen, a clinical-stage US vaccine developer, today announced the publication of results from its Phase II human challenge study of Bris2007 M2SR, the company’s investigational, supra-seasonal, live, single-replication, intranasal influenza (flu) vaccine. 2 August 2021
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.